<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date**</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
</table>
| 2     | CDR Reviewers' Reports Completed  
- Reviewers selected and contracted  
- Literature search and selection completed  
- Systematic review of clinical data completed  
- Critical appraisal of pharmacoeconomic (PE) data completed  
- Clinical and PE reports written  
- Reports edited and finalized  
| 3     | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7             | 2006-Aug-10     | 2006-Sep-01 | Request for extension received August 3, 2006. Extension granted, new due date for manufacturer's comments is September 1, 2006. New target CEDAC date October 18, 2006. |
| 4     | Reviewers' Reply to Manufacturer's Comments Completed | 7             | 2006-Sep-13     | 2006-Sep-13 | |
| 8     | Embargo Period***  

9 (a) Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5 | |

OR

9 (b) Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer  

OR

9 (c) Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request) | 25 | Depends on Meeting Dates | |

10 Final Recommendation sent to Drug Plans, ACP, and Manufacturer | 5 | |

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.